Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 9/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111678 | 0.87 | FBP1 (0.58) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL25932763 | 0.82 | PPARA (0.55) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL659739 | 0.80 | ALDH1A1 (0.58) | PPARACYP3A4CYP1A2TSHRPPARG | |
| SCHEMBL12670823 | 0.79 | FBP1 (0.56) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL12804549 | 0.79 | PPARA (0.56) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL198569 | 0.78 | PPARA (0.51) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL3485006 | 0.78 | FBP1 (0.55) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL14092161 | 0.78 | FBP1 (0.55) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL4423002 | 0.78 | PPARA (0.59) | FBP1PPARACYP3A4ABCB11CYP1A2 | |
| SCHEMBL4681650 | 0.77 | FBP1 (0.54) | FBP1PPARACYP3A4ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | CNR1, CNR2, GPR18 | FBP1 3245/4885PPARA 490/4885CYP3A4 375/4885 |
| US-20080021087-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | FBP1 3245/4885PPARA 490/4885CYP3A4 375/4885 |
| US-20090023800-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | FBP1 3245/4885PPARA 490/4885CYP3A4 375/4885 |
| US-20070099990-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | FBP1 3245/4885PPARA 490/4885CYP3A4 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.